Phenotypes such as dietary salt intake in meta-regression models. Last but not least, in this study, we only focused on eNOS polymorphisms, and did not evaluate other genes or polymorphisms. It is possible that the potential roles of G894T or 4b/a or T2786C polymorphisms are diluted or masked by other genegene or gene-environment interactions. Thus, the jury must refrain from drawing a conclusion until a large, well-performed Chinese study confirms or refuses our results. Taken together, via a comprehensive meta-analysis, we once again ascertained the role of eNOS G894T and 4b/a polymorphisms on the development of hypertension for Asian populations and T2786C polymorphism for Whites. Although the publication bias was maximally avoided, presence of between-study heterogeneity could not be fully explained by our subgroup and metaregression analyses. Although further analyses are warranted to investigate eNOS adjacent markers in a wider context, future studies should center on gene-gene and gene-environment interactions, as well as haplotype patterns. Gemtuzumab ozogamicin is an immunoconjugate between a humanized IgG4 CD33 monoclonal antibody and a calicheamicin–c1 derivative. The target antigen is expressed on myeloid cells as well as on leukemic blasts from more than 80% of AML patients, but is absent on pluripotent Reversine hematopoietic stem cells and non-hematopoietic cells. Binding of GO to the CD33 antigen leads to internalization of the drug-antigen complex and hydrolytic release of the toxic calicheamicin component. GO was approved for the treatment of elderly patients with relapsed AML not considered candidates for standard chemotherapy, after demonstration of an approximately 25% overall response rate in this patient population. More recent studies have suggested a benefit of combining GO with other chemotherapeutics, and ongoing clinical trials are expected to further define the exact role of GO in AML therapy. However, the optimal schedule and dosing of GO remains unclear. Recent press-release of the drug manufacturing company determined that the drug is currently withdrawn from the market due to lack of survival benefit and excessive toxicity in SWOG S0106 randomized clinical trial where GO was added to the regular induction treatment in younger AML patient as first line. However, significant efficacy in elderly patients receiving GO as monotherapy or with low dose cytotoxics is still debated. Given the significant toxicities associated with current clinical use of GO, prospective identification of the patients most likely to benefit from GO and determination of the most efficacious and least toxic GO administration schedule is of considerable interest. Classical population pharmacokinetic analysis of GO was performed for the standard dose, it showed decrease in volume of distribution and clearance rate during second drug infusion, probably due to lowering of the blast burden, which is responsible for specific CD33 mediated drug clearance. However, this standard approach failed to provide the information needed for individualization of the GO dose and administration schedule, as well as for optimal combination with other cytotoxic drugs.